DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ( ...

Cancer and its associated treatments represent a multifaceted challenge that affects both the physical and psychological well-being of patients. Over the ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Effective injury prevention programmes (IPPs) hold promise for mitigating ACL injuries in female handball players, yet ...

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...

Cardarine GW 501516 is a potent PPARβ and PPARδ receptor agonist. It is often misclassified as one of the known selective ...